On January 3, 2018 FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), reported that Martin Meeson, President and COO of FUJIFILM Diosynth Biotechnologies U.S.A., is scheduled to present at EBD’s Biotech Showcase 2018 event during the 36th Annual J.P. Morgan Healthcare conference week in San Francisco, California (Press release, Fujifilm, JAN 3, 2018, View Source [SID1234522852]). The presentation is scheduled to take place Tuesday, Jan. 9, 2018 at 3:00 PM PST. The presentation will be part of the Yosemite -B Track (Ballroom Level).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Meeson’s presentation will focus on FUJIFILM Diosynth Biotechnologies’ investment strategies to support the growth and expansion required to meet the global demands in the delivery of biologics, gene and cell therapies.

The Biotech Showcase 2018 will take place at the Hilton San Francisco Union Square located at 333 O’Farrell Street – Ballroom Level, San Francisco, California 94102

On January 3, 2018 INSYS Therapeutics, Inc. (NASDAQ:INSY), reported that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will present at the 36th annual J.P. Morgan Healthcare Conference as follows(Press release, Insys Therapeutics, JAN 3, 2018, View Source;p=RssLanding&cat=news&id=2324652 [SID1234522833]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, Jan. 11, 2018
Time: 7:30 a.m. Pacific Standard Time
Location: San Francisco – Westin St. Francis Hotel
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Investors section of company’s website at View Source, under Presentations & Events. The presentation slides will be available during the conference, accessible at the same webpage.

In addition to making a presentation, management will also provide an overview of the company’s business in one-on-one meetings with investors who are registered to attend the conference.

On January 3, 2018 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), ("Onxeo" or the "Company"), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, reported that its management team will attend the following key investor and partnering conferences in the first half of 2018 (Press release, Onxeo, JAN 3, 2018, View Source [SID1234522855]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor meetings during the JP Morgan Healthcare Conference 2018
January 8-11, 2018
San Francisco, US

ODDO BHF Forum
January 12, 2018
Lyon, France

BIO-Europe Spring
March 12-14, 2018
Amsterdam, The Netherlands

CM-CIC Market Solutions Forum by ESN
March 22-23, 2018
Paris, France

Portzamparc MidCap 2018 Conference
April 4-5, 2018
Paris, France

BIO International Convention
June 4-7, 2018
Boston, US

SG CIB Nice Conference 2018
June 7-8, 2018
Nice, France

On January 3, 2018 Juno Therapeutics, Inc. (NASDAQ:JUNO) reported that it will webcast its presentation at the 36th Annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT on Tuesday, January 9, 2018 (Press release, Juno, JAN 3, 2018, View Source [SID1234522883]). The presentation will feature a business overview and update by Hans Bishop, Juno’s President and Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be accessible on the Investor Relations page of Juno’s website at www.JunoTherapeutics.com. A replay of the presentation will be available at the same location for 30 days following the conference.

On January 3, 2018 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that it will hold its fourth-quarter and full-year 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Friday, February 2 (Press release, Merck & Co, JAN 3, 2018, View Source [SID1234522834]). During the call, company executives will provide an overview of Merck’s performance for the quarter and year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at View Source A replay of the webcast, along with the sales and earnings news release and supplemental financial disclosures, will be available at www.merck.com.

Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 9899537. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 9899537. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.